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Background: Malignant gliomas are the most common form of primary malignant brain tumor. It has recently
been suggested that genetic changes are involved in the progression of malignant gliomas. In previous studies, a
novel gene, p42.3, was characterized as a tumor-specific gene that encodes a mitosis phase–dependent expression
protein which is expressed in gastric cancer, but not in matched normal tissues.
Methods: In a series of 200 human brain gliomas and 13 normal tissues, we performed RT-PCR and mRNA in situ
hybridization for analysis of p42.3 gene expression in gliomas, including astrocytoma (grade 2), oligoastrocytomas
(grade 2), anaplastic oligoastrocytomas (grade 3), glioblastomas (grade 4) and normal tissues. Also, the mRNA expression
was detected in gliomas by in situ hybridization. After producing polyclonal antibody to p42.3, we further tested p42.3
protein expression in astrocytomas and glioblastomas by immunohistochemistry and Western blot analysis.
Results: Our results demonstrated that overexpression of the p42.3 gene is detected in gliomas, but not in normal brain
tissues. Importantly, p42.3 mRNA expression is correlated with the pathological features of gliomas. In addition, p42.3
protein is expressed in both the cytoplasm and the nucleus in astrocytomas, whereas this protein appeared in the
cytoplasm in glioblastomas.
Conclusions: These results indicate that p42.3 might be involved in carcinogenesis as a potential molecular marker for
malignant gliomas.
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Gliomas are the most common human brain tumors; they
account for more than 40% of central nervous system
neoplasms [1]. These tumors are classified as astrocytomas,
oligodendrogliomas (ODs) or oligoastrocytomas (OAs).
With respect to their malignant progression, they are also
categorized as grade 1, 2, 3 and 4 by the World Health
Organization [2,3]. Grades 1 and 2 indicate benign tumors
and grades 3 and 4 are malignant ones [4]. The most
aggressive astrocytoma is referred to as glioblastoma multi-
forme (GBM) (grade 4) [5]. GBMs may develop de novo* Correspondence: zlwtt@aliyun.com; youyounglu@sina.com
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unless otherwise stated.(primary GBMs) or by progression from low-grade or ana-
plastic astrocytomas (secondary GBMs) [6,7]. Molecular
genetic study researchers have confirmed that genetic
changes involved in the progression of malignant gliomas
include loss of heterozygosity 10 (LOH10), phosphatase
and tensin homolog (PTEN), tumor protein p53 (TP53),
epidermal growth factor receptor (EGFR) and P16 [8].
Despite advances in surgical and clinical neurooncology,
the prognosis for patients with high-grade gliomas remains
poor, owing to the insidious infiltration of these tumors
into adjacent brain tissue [9,10]. Therefore, scientists need
to perform more studies to clarify the detailed molecular
mechanisms of gliomas and find biomarkers for early
diagnosis or effective therapeutic targets in order to
improve the prognosis for patients with malignant gliomas.
In previous studies, we confirmed that p42.3 gene
expression is cell cycle–dependent in gastric tumor cells
and specifically expressed in gastric cancer, but not ind. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
g/publicdomain/zero/1.0/) applies to the data made available in this article,
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to predict the p42.3 gene expression profile in brain and
liver tissues by digital Northern analysis. We confirmed
gene expression in five kinds of tumor cell lines and fetal
tissues, including those from the brain and liver. p42.3
gene expression was studied in clinical specimens of
gliomas and in normal human brain tissues for further
analysis of the correlation between p42.3 gene expression
and malignant progression. Overall, our data support
the hypothesis that the p42.3 gene may be involved in
tumorigenesis and might be a potential molecular marker
for distinguishing different grades of malignant gliomas.
Methods
Ethics statement
All patients provided their written informed consent
to participate in the study, and the clinical study was
approved by the Institutional Review Board of Beijing
Tiantan Hospital.
Tissue samples
In this study, we used 162 paraffin-embedded samples,
51 nitrogen-frozen samples of human brain gliomas
which that had been resected surgically and 13 normal
tissues derived from traumatic decompression operations.
Histopathologic analyses were independently performed
by two pathologists.
RT-PCR
Total RNA was extracted using TRIzol reagent. cDNA was
synthesized from total RNA according to the manufac-
turer’s instruction manual (Promega, Madison, WI, USA).
RT-PCR for analysis of the p42.3 gene expression was per-
formed using two pairs of primers (5′-TGG CAT CTT
TAC TGG ACT GG-3′ and 5′-TGG CAC CTC GTG
GAT AGA GC-3′; 5′-CCA GCG GCT ACC TGA CCT
TC-3′and 5′-CAG CTC CTT CAT CTG CTT CAG-3′).
The RT-PCR conditions were as follows: sufficient de-
naturing at 95°C for 50 seconds, denaturing at 94°C
for 50 seconds, annealing at 55°C for 50 seconds,
elongation at 72°C for 50 seconds (30 cycles) and a
final cycle at 72°C for 10 minutes. β-actin served as
the internal positive control. The RT-PCR products
were examined by gel electrophoresis.
mRNA in situ hybridization
The RT-PCR fragment of the p42.3 gene was cloned into
the pGEM-T easy vector system (Promega) that con-
tained SP6 and T7 promoters. After sequencing, to
confirm the orientation of the insert, the plasmids
were linearized by either ApaI or SacI enzyme digestion.
Digoxigenin (DIG)-labeled, anti-sense- or sense-strand
RNA probes were prepared by in vitro transcription with
T7 RNA polymerase and SP6 RNA polymerase accordingto the manufacturer’s instruction manual (Roche). A tissue
array was incubated overnight at 43°C in prehybridization
buffer containing 5 ng/μl of a sense or antisense
DIG-labeled RNA probe. Detection of hybridization
was undertaken using a DIG nucleic acid detection kit
(Roche Applied Science, Indianapolis, IN, USA) according
to the manufacturer’s instructions. Hybridization with
sense-strand RNA probes was used as a negative control.
Antibody generation and identification
Three peptides were selected on the basis of analysis
using DNASTAR software (DNASTAR, Madison, WI,
USA) and were synthesized by Shenggong Biological
Company (Shenggong, China). We then immunized
rabbits using these synthesized peptides to generate
polyclonal antibodies. Preimmune and immune sera
were harvested. The fragment of cDNA including CDS
(coding sequence) was amplified by nested PCR and
cloned into prokaryotic expression vector PET-28a. The
p42.3 protein was expressed by Escherichia coli BL21
and purified by nickel nitrilotriacetic acid (Ni-NTA)
agarose. The purified p42.3 protein was identified by
matrix-assisted laser desorption/ionization time-of-flight
mass spectrometry, and Western blot analysis was
performed to identify the specificity of polyclonal
antibodies. Polyclonal antibody to the p42.3 protein
was isolated using purified protein and Sepharose 4B
according to the manufacturer’s instructions (Borunlaite
Science&Technology Company, Bejing, China).
Western blot analysis
For protein analysis, tissues were lysed in protein lysis buf-
fer. Protein (100 μg) was separated by 12% Tris-glycine
polyacrylamide gel and transferred to a polyvinylidene
fluoride membrane by electrophoretic blotting at 90 V for
2 hours. The membrane was blocked with 5% nonfat dry
milk in 0.1% phosphate-buffered saline with Tween 20
(PBST) and was incubated with a 1:100 dilution of poly-
clonal antibody at 4°C overnight. The blot was then
washed in PBST and incubated for 2 hours with horserad-
ish peroxidase–conjugated secondary antibody goat anti-
rabbit immunoglobulin G (IgG) (1:1,000) and washed in
PBST. The membrane was then developed using an elec-
trochemiluminescence Western blotting detection reagent
system (Amersham, Little Chalfont, UK) according to the
manufacturer’s instructions.
Immunohistochemistry
Immunohistochemistry was performed as follows. Briefly,
sections were deparaffinized by incubation at 70°C for
2 hours. Next, the slides were subjected to antigen retrieval
by autoclave heating in an ethylenediaminetetraacetic acid
buffer for 2.5 minutes and left to cool down to room
temperature. After that, slides were then incubated in 3%




Grade Total cases, N p42.3 expression, n Percent
positive
Positive Negative
Astrocytoma 2 11 1 10 9.1%
OA 2 10 1 9 10%
Anaplastic OA 3 6 0 6 0
GBM 4 11 5 6 45.5%
Normal tissue 9 0 9 0
aGBM, Glioblastoma multiforme; OA, Oligoastrocytoma.
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ethanol gradient, and then they were incubated in 10%
nonfat dry milk to reduce nonspecific binding. Afterward,
the slides were sequentially incubated with purified anti-
p42.3 antibody (1:50), biotinylated goat anti-mouse IgG
and avidin-biotin complex were added for 30 minutes at
room temperature and the slides were developed with
diaminobenzidine (Dako, Carpinteria, CA, USA).
Statistical methods
A χ2 test (SPSS 10.0 for Windows, Chicago, IL, USA) was
performed to analyze the expression of p42.3 in grade 2
gliomas, and grade 4 GBMs were examined by RT-PCRTable 2 Frequency of p42.3 gene expression in gliomas ident
Tumor type (histological grade) p42.3 expression (%) S




















aGBM, Glioblastoma multiforme; OA, Oligoastrocytoma; OD, Oligodendroglioma.(Table 1). Logistic regression analysis (SAS 8.01 software;
SAS Institute, Cary, NC, USA) was carried out to assess
the frequency of p42.3 gene expression in gliomas identi-
fied by mRNA in situ hybridization (ISH) (Tables 2 and 3).
Statistical significance was set at P < 0.05.
Results
Prediction of p42.3 gene expression by digital Northern
analysis
We knew little about the novel gene p42.3 after cloning
its full-length cDNA. However, bioinformatics proved to
be a very useful tool in helping us to find clues for a
successive study; therefore, we predicted the expression
profile by digital Northern analysis of the National Center
for Biotechnology Information (NCBI) reference sequence.
The results showed that the p42.3 gene is highly expressed
in several cancer tissues, such as prostate adenocarcinoma,
brain GBM, breast carcinoma and colon adenocarcinoma,
as well as in embryonic kidney tissue (Figure 1).
mRNA expression of the p42.3 gene is associated with
degree of malignancy in gliomas
Digital Northern analysis showed that the p42.3 gene
is expressed in brain GBMs and confirmed that p42.3 is
expressed in human fetal brain tissue as well. Therefore, we
performed RT-PCR to examine its expression in gliomas,ified by mRNA in situ hybridizationa
ex Age <50 yr, n Age ≥50 yr, n Total (N)
ale 5 1 6
emale 4 0 4
ale 30 4 34
emale 18 1 19
ale 1 0 1
emale 1 0 1
ale 10 4 14
emale 4 1 5
ale 1 0 1
emale 1 0 1
ale 4 5 9
emale 4 1 5
ale 0 1 1
emale 2 0 2
ale 5 0 5
emale 2 0 2
ale 9 5 14
emale 4 1 5
ale 13 10 23
emale 6 4 10
Table 3 Analysis of correlation between p42.3 gene
expression and pathological gradea
Characteristics OR 95% CI P-value
Sex 0.4366
Female Ref
Male 1.384 0.610 to 3.137
Age 0.5411
<50 yr Ref
≥50 yr 0.751 0.299 to 1.884
Grade 0.0041*
2 Ref
3 and 4 3.089 1.430 to 6.675
aCI, Confidence interval; OR, Odds ratio; Ref, Reference value.
*Statistically significant.
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OAs (grade 3), GBMs (grade 4) and corresponding normal
tissues. The results showed that the positive frequency of
this gene expression was similar between astrocytomas
(1 of 11, 9.1%) and OAs (1 of 10, 10%); however, we
found that p42.3 gene was expressed in 5 (45.5%) of
11 GBMs (Figure 2A and B) and was not expressed in 6
anaplastic OA samples. Moreover, this gene was undetect-
able in nine normal brain tissue samples (Figure 2C and
Table 1). The prostate cell line PC3 served as a positive
control. Using mRNA in situ hybridization with a variety
of tissues, we examined p42.3 gene expression in brain
gliomas. Table 2 shows that the expression of this gene was
positive in 10 (15.9%) of 63 astrocytomas, 2 (12.5%) of 16
OAs, 3 (30%) of 10 anaplastic OAs, 2 (9.52%) of 21 ODsFigure 1 Prediction of p42.3 gene expression in tumor cell lines and t
Biotechnology Information (NCBI) reference sequence showed that the p42
prostate adenocarcinoma, brain glioblastoma multiforme, breast carcinomaand 19 (36.5%) of 52 GBMs. In contrast, the p42.3 gene
was not expressed in four normal brain tissues (Figure 2C
and Table 2). More importantly, the statistical significance
of expression between grade 2 and grade 4 gliomas was
0.038 (P < 0.05) (Table 1), and the expression of the p42.3
gene was significantly different between low-grade
(grade 2) gliomas and high-grade (grades 3 and 4) gliomas
(P < 0.01), but there was no statistically significant
difference associated with age or sex (Table 3).
Polyclonal antibody binding of p42.3 protein
We produced polyclonal antibody to the p42.3 protein
to analyze the corresponding protein expression and
generated six sets of rabbit antiserum against three syn-
thetic peptide fragments of the p42.3 protein. The p42.3
protein was expressed in E. coli and purified by Ni-NTA
agarose (Figure 3A). Western blot analysis showed that
two of the six sets could specifically bind intact protein
expressed in E. coli (Figure 3B).
Frequent expression of p42.3 protein in glioblastoma
multiforme
Western blot analysis was carried out to examine the
p42.3 protein expression in gliomas and normal brain
tissues. The glioma specimens included eight GBM
samples (grade 4), four OA samples (grade 2), three
anaplastic OA samples (grade 3), and three normal
tissue samples. The results showed that p42.3 protein
was frequently expressed in all eight GBM samples
and detectable in one OA sample and one anaplastic
OA sample. p42.3 protein was not expressed in theissues. Digital Northern analysis of the National Center for
.3 gene is expressed in several kinds of cancer tissue, including
and colon adenocarcinoma, as well as in embryonic kidney tissue.
Figure 2 Examination of p42.3 in brain gliomas. (A) and (B) p42.3 expression was confirmed in five glioblastoma multiforme (GBM) samples,
one astrocytoma sample and one oligoastrocytoma (OA) [it is correct here as written, “astrocytoma” and “oligoastrocytoma”.] sample by RT-PCR.
(C) p42.3 was not expressed in normal brain tissue. The PC3 cell line served as the positive control [1]. (D) mRNA in situ hybridization analysis
showed that p42.3 was significantly overexpressed in anaplastic OA (b) and GBM (c), but not in normal brain tissue (a).
Figure 3 Generation and identification of the p42.3 antibody. (A) p42.3 was expressed in Escherichia coli and purified by nickel nitrilotriacetic
acid agarose. (B) Western blot analysis showed that two sets of rabbit antiserum could specifically bind the purified protein of p42.3. (C) Mass
spectrometry analysis confirmed that the sequence of purified protein corresponded to that of p42.3. (D) Mascot database (Matrix Science,
Boston, MA, USA) search results.
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Figure 4 Examination of p42.3 in glioma tissue samples by Western blotting. (A) p42.3 protein was expressed in eight glioblastoma
multiforme samples (grade 4, lanes 1 to 8) and one anaplastic oligoastrocytoma (OA) sample (grade III, lane 9). (B) p42.3 was detectable in two
OA samples (grade 2, lanes 6 to 9; lanes 4 and 5 are anaplastic OA). The protein was not detected in three normal brain tissue samples (lanes 1 to 3).
(C) Tubulin served as the internal control.
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control (Figure 4).
p42.3 protein is differentially located between
astrocytomas and glioblastomas
We further performed immunohistochemistry on ten
astrocytoma samples and ten GBM samples to test p42.3
expression. Our results show that this protein was
expressed in both astrocytomas (tumor grades 5 ≥ ++, 5+)
and GBMs (tumor grades 4 ≥ ++, 6+). Moreover, the loca-
tion of p42.3 expression is different in these two gli-
oma types. p42.3 protein was tested in both theFigure 5 p42.3 expression in astrocytomas and glioblastomas evaluat
cytoplasm (original magnification, ×200) (A) and the nucleus (original mag
expressed in the cytoplasm (original magnification, ×200) (C), but not in th
samples (n = 10). Logistic regression analysis (SAS 8.01 software) confirmed
tumors was significant (P < 0.01). No statistically significant difference assoccytoplasm and nucleus in nine of ten astrocytoma samples
(Figure 5A and B), especially the protein highly expressed
in the nucleus. In contrast, this protein was strongly
expressed in the cytoplasm in only nine of ten GBM
samples, and there was little expression of p42.3 protein
in the nucleus (Figure 5C and D).
Discussion
In order to find out whether key genes are involved in both
cell-cycle regulation and carcinogenesis, we screened out a
cDNA fragment between the G1 and S phases of the cell
cycle in a tumor cell line, BGC823, by mRNA differentialed by immunohistochemistry. p42.3 was expressed in both the
nification, ×400) (B) in the astrocytoma samples (n = 10). p42.3 was
e nucleus (original magnification, ×400) (D), in the glioblastoma
that the statistical difference between grade 2 and grades 3 and 4
iated with age or sex was found.
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designated p42.3 [GenBank:DQ150361]. The p42.3 gene is
located on human chromosome 9q34.3 and is composed
of five introns and six exons. It encodes a 389–amino acid
(42.3 kDa) protein with functional motifs. In our pre-
vious study of gastric tumor cell lines and gastric
cancer, we showed that the p42.3 gene might be involved
in cell-cycle regulation and might play a role in gastric
cancer development [11].
A homolog of p42.3 is present in the mouse, in which
it is expressed in the early neuroectoderm of the embryo
[12]. The high conservation of the p42.3 gene in mammals
also suggests that this gene might serve important
roles in cell biology. Digital Northern analysis of the
NCBI reference sequence showed that the p42.3 gene
is expressed in GBMs and other malignancies, which
gave us important information about this novel gene.
Our examination validated that the p42.3 gene was
indeed expressed in various cancer cell lines and fetal
tissues, including the brain.
Gliomas are the most frequently encountered human
brain tumors, and the prognosis for glioma patients
worsens with increasing tumor grade. Patients with
high-grade gliomas (for example, anaplastic astrocytomas
and GBMs) have a median survival time of 9 months, and
only 5% to 10% of patients can survive as long as 2 years
[13,14]. Accumulation of multiple genetic abnormalities
lead to human malignant gliomas. Inactivation of the
p16-cdk4-pRb pathway has been implicated in the
progression to grade 3 astrocytoma [15,16]. Secondary
GBMs have a high incidence of TP53 mutations
(>65%), the majority of which are already present in low-
grade or anaplastic astrocytomas [17]. LOH10 is the most
frequent genetic alteration in GBMs, occurring in 60% to
80% of cases [18-20]. Deletion of PTEN [21,22] and over-
expression of EGFR have also frequently been found in
GBMs [23,24]. These previous studies have elucidated the
partial molecular mechanisms of malignant progression of
gliomas, although the precise molecular events involved
in the process are not yet known. Therefore, finding crit-
ical genes involved in the progression of malignancy might
effectively confer an improved prognosis for patients with
high-grade gliomas by application of targeted therapies.
The expression profile of the p42.3 gene was the
primary focus of our research in this study, in which we
analyzed clinical tumor samples taken from patients with
gliomas in China. The p42.3 gene was confirmed to be
expressed in these glioma samples, but not in normal
human brain tissues, at both the mRNA and protein
levels. More importantly, the percentage of p42.3 mRNA
expression increased in tandem with the progression of
glioma malignancy, with statistically significant differences
found between grade 2 (benign) tumors and grades 3 and
4 (malignant) tumors. This evidence is important evidencesupporting the hypothesis that the p42.3 gene might not
only be involved in carcinogenesis but also play a role in
the progression of glioma malignancy. Moreover, the
different locations of p42.3 between astrocytoma and
GBM cells suggests that this protein has different roles in
high- and low-grade gliomas. Further study is needed to
clarify these detailed functions in this process.
Interestingly, we found the same expression pattern in
gliomas: The p42.3 gene was expressed in glioma tumor
tissue samples, but not in corresponding normal tissue, in
our Chinese patient population. It is generally believed that
a fetal protein, highly expressed at fetal stages and quickly
shut down after birth, could recur in different tumor
stages. Such molecules are likely to be a tumor marker and
might act as an oncogene involved in carcinogenesis
[25,26]. We found that the expression profile of the p42.3
gene was in agreement with the criteria mentioned above.Conclusion
In our present study, we establish the expression pattern
of a novel gene, p42.3, which suggests that this gene is
associated with glioma malignancy. Moreover, we found
that p42.3 mRNA expression was correlated with the
degree of glioma malignancy. These results provide
important clues to inform further studies of this novel
gene and might be useful in diagnosing gliomas. The
location of this protein may help investigators to discern
high- and low-grade gliomas.Competing interests
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